Clinical practice guidelines in Alzheimer's disease;Guia de practica clinica en la enfermedad de Alzheimer

Revista Neurologica Argentina

Volumn 31, Issue 2, 2006, Pages 140-144

  Abel, C ^a   Allegri, R F ^a   Arizaga, R L ^a   Baumann, D ^a   Bavec, C ^a   Caccuri, R ^a   Dillon, C ^a   Famulari, A ^a   Frontera, S ^a   Garau, M L ^a   Genovese, O ^a   Golimstok, A ^a   Labos, E ^a   Lischinsky, A ^a   Mangone, C A ^a   Monti, L ^a   Ollari, J A ^a   Reich, E ^a   Sarasola, D ^a   Stein, G ^a   Taragano, F ^a   Ure, J ^a   Zuin, D ^a   more..

^a Sociedad Neurológica Argentina ^*

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; ELECTROENCEPHALOGRAPHY; HUMAN; PRACTICE GUIDELINE; REVIEW;

EID: 46749127487     PISSN: 03250938     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Allegri RF. Estudios complementarios para el diagnóstico de las demencias. En: Mangone CA, Allegri RF, Arizaga RL & Ollari JA (Eds.). "Enfermedad de Alzheimer Enfoque Actual". Ediciones Libros de la Cuadriga, Buenos Aires 1995 (pp. 217-246).
2. Alzheimer Europe response to the preliminary Nice recommendations. 13 feb 2006.
3. Areosa S., Scherriff F.: Memantine for dementia. Cochrane Database Syst. Rev. 2003.
4. Arizaga RL. Epidemiología de la demencia. En: Mangone CA, Allegri RF, Arizaga RL & Ollari JA (Eds.). "Demencia. Enfoque Multidisciplinario". Editorial Polemos, Buenos Aires 2005 (pp. 523-544).
5. Baldereschi M, Amato MP, Nencini P, Pracucci G, Lippi A, Amaducci L, Gauthier S, Beatty L, Quiroga P, Klassen G, et al. Cross-national interrater agreement on the clinical diagnostic criteria for dementia. WHO-PRA Age-Associated Dementia Working Group, WHO-Program for Research on Aging, Health of Elderly Program. Neurology. 1994 Feb; 44 (2): 239-42.
6. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994 Dec; 51 (12): 1198-204.
7. Brink T L; Yesavage J A; Lum O; Heerema P. et al. Screening tests for geriatric depression. Clinical Gerontologist 1982; 1(1): 37-43. Spanish version by Gonzalez Felipe M A.
8. Brodaty H, Low LF, Gibson L, Burns K. What Is the Best Dementia Screening Instrument for General Practitioners to Use? Am J Geriatr Psychiatry 2006 May; 14 (5): 391-400.
9. Brodaty H, Pond D, Kemp NM et al. The GPCOG: A New Screening Test for Dementia Designef for general Practice. J Am Geriatr Soc, 2002: 50: 530-4.
10. Buschke H, Kuslansky G, Katz M, et al. Screening for Dementia with the Memory Impairment Screen. Neurology 1999: 52: 231-8.
11. CAED (Consortium Argentino para el Estudio de la Demencia). Normativas para el diagnostico de demencia en general y demencias corticales tipo Alzheimer. Rev. Neurol. Argentina 1995; 20: 103-5.
12. CAED (Consortium Argentino para el Estudio de la Demencia). Normativas para el diagnóstico de la demencia subcortical. Revista Neurológica Argentina 1998; 23: 54-55.
13. Corey-Bloom J, Thal LJ, Galasko D, et al. Diagnosis and evaluation of dementia. Neurology 1995; 45: 211-8.
14. Desai AK & Grossberg GT. Diagnosis and treatment of Alzheimer's disease. Neurology 2005; 64 (12) Suppl 3: S34-39.
15. Doody RS et al. Practice parameter. Management of dementia. (an evidence based review)-Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-66.
16. Fernández A. Focal temporoparietal slow activity in Alzheimer's disease revealed by magnetoence-phalography. Biol Psychiatry 2002; 52 (7): 764-70.
17. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
18. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994 Sep; 51 (9): 888-95.
19. Grupo de Trabajo de Neuropsicología Clínica de la Sociedad Neurológica Argentina. El Mini Mental State Examination en la Argentina: instrucciones para su administración. Revista Neurológica Argentina 1999 a; 24: 31-35.
20. Hachinski VC, Lliff LD, Zilhka et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-7.
21. Hamilton M. A rating scale in depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
22. Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. Dement Geriatr Cogn Disord 2003; 16 (3): 170-80. Erratum in: Dement Geriatr Cogn Disord. 2005; 19 (2-3): 170. Irani, S [corrected to Irani, SR].
23. Hogervorst E, Barnetson L, Jobst KA, Nagy Z, Combrinck M, Smith AD. Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. Dement Geriatr Cogn Disord 2000 Mar-Apr; 11 (2): 107-13.
24. Hughes CP, Berg L, Danziger WL, et al. A new rating scale for staging of dementia. B J Psychiatry 1982; 140: 566-572.
25. th Annual International Conference of the IEEE EMBS, San Francisco CA, USA, Sept 1-5, 2004.
26. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.Int Psychogeriatr. 1998 Sep;10 (3): 271-302. Corrected and republished from: Int Psychogeriatr 1997; 9 Suppl 1: 191-222; discussion 247-52.
27. Kaduskiewicz H, Zimmerman D. et al.Cholinesterasa inhibitors for patients with Alzheimer'disease: systematic review of randomised clinical trials. BMJ 2005, 331; 321-7.
28. Kukull WA, Larson EB, Reifler BV, Lampe TH, Yerby MS, Hughes JP. The validity of 3 clinical diagnostic criteria for Alzheimer's disease. Neurology 1990 ep; 40 (9): 1364-9.
29. Lanctot KL. Et al. Efficcacy and safety of cholinesterase inhibitor in Alzheimer's disease. A metaanalysis. CMAJ 2003.Sep 16; 169 (6): 557-64.
30. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, Becker JT, DeKosky ST. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999 Oct 12; 53 (6): 1292-9.
31. Loueman E. et al. The clinical and cost effectiveness of donepecil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2005, Vol 10: No 1.
32. a Ed.). Editorial Médica Panamericana, Buenos Aires 2002, pp. 712-29.
33. Mangone CA. Metodología diagnóstica de la demencia tipo Alzheimer. Alcmeon 1991; 4: 445-65.
34. Mayeux el al-Utility of the Apolipoprot E genotype in the diagnosis of AD-N Engl J Med 1998; 338 (18): 1326.
35. Mayeux R et al. The clinical evaluation of patients with dementia. En Whitehead P (ed.): Dementia; F.A. Davis Co., Philadelphia 1993.
36. McShane R., Aerosa SA., Minakaran N. Memantine for dementia. The cochrane database of systematic reviews 2006.Issue 2, Art. No CDOO3154. DOI: 101002/1451858, CD 003154.
37. Meiran N; Stuss D; Guzmán A; et al. Diagnosis of dementia. Methods for interpretation of scores of 5 neuropsychological tests. Arch Neurol 1996; 53: 1043-1054.
38. rd. Ed.) Butterworth-Heinemann (Elsevier Science USA) 2003, pp. 1-12.
39. Myers AJ The genetics of late Alzheimer's disease. Cuur Op Neu 2001; 14: 433-40.
40. Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM, McDonald B,Litchfield S, Barnetson L, Jobst KA, Smith AD. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Disord. 1998 Jul-Aug; 9 (4): 219-26.
41. NICE Appraisal consultation document. Feb. 2006.
42. O'Mahony D et al. Event-related potential prolongation in Alzheimer's disease signifies frontal lobe impairment: evidence from SPECT imaging.Journal of Gerontology Series A: Biological Sciences and Medical Sciences, Vol 51, 102-M107, 1996.
43. Ollari JA & Diez MV. Neurobiología del Envejecimiento. En: Mangone CA, Allegri RF, Arizaga RL & Ollari JA (Eds.). Demencia. Enfoque Multidisciplinario. Editorial Polemos, Buenos Aires 2005 (pp. 49-69).
44. Ollari JA, Allegri RF, Arizaga RL & Mangone CA. Tratamiento farmacológico de las demencias. En: Mangone CA, Allegri RF, Arizaga RL & Ollari JA (Eds.). Demencia. Enfoque Multidisciplinario. Editorial Polemos, Buenos Aires 2005 (pp. 523-544).
45. Polich J et al. Alzheimer's disease and P 300: review and evaluation of task and modality. Current Alzheimer Research 2005; 2, 5: 515-25.
46. Prinz PN et al. EEG markers of early Alzheimer's disease in computer selected tonic REM sleep. EEG Clin Neurophysiol 1992; 83 (1): 36-43.
47. Reisberg B; Borenstein J; Salob F; Franssen E. et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (5): 9-15.
48. Reisberg B; Ferris S; DeLeon M; Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 9: 1136-9.
49. Rosen GW, Mohs R, Davis JL. A new rating scale for Alzheimer's Disease. Am J Psychiatry 1984; 141 (11): 1356-60.
50. Saunders et al-Associaton of apolipoprotein E allele E4 with late-onset familial and sporadic AD- Neurology 1993; 43: 1467-72.
51. Scanlan J, Borson S.The mini-cog: receiver operating characteristics with expert and näive raters. Int J Geriatr Psychiatry 2001 Feb; 16: 216-22.
52. Schreiter-Gasser U et al. Quantitative EEG analysis in early onset Alzheimer's disease: correlations with severity, clinical characteristics, visual EEG and CCT. EEG Clin Neurophysiol 1994; 90 (4): 267-72.
53. Soininen H et al. Changes in absolute power values of EEG spectra in the follow up of Alzheimer's disease. Acta Neurol Scand 1991; 83: 133-6.
54. Swanwick GR et al. Clinical application of electrophysiological markers in the differential diagnosis of depression and very mild Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 60 (1): 82-6.
55. Tandon A, el al Molecular genetics of Alzheimer's disease. Curr OP Ne 2000; 13: 377-84.
56. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999 Feb; 66 (2): 184-8.
57. www.alzheimer.uktreatmentthereactionoftheNicestudy.htm.
58. Zhukareva Vm et al- Sporadic Pick disease: a taupathy characterized by a spectrum of pat. Tau isoforms in gray and white matter. Ann Neurol 2002; 51: 730-9.